Increased serum glutamate in depressed patients
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Glutamate concentration was determined in serum from endogenous and neurotic depressive patients, in persons with schizophrenia or schizoaffective disorder, and in normal subjects. The mean serum glutamate level in the endogenous and neurotic depressive patients was found to be significantly higher than in any of the other groups. No other statistically significant differences were found. Statistical analysis revealed that the elevated serum glutamate concentration in the endogenous and neurotic depressive patients was probably caused by medication. These results are discussed in view of the effect of antidepressants upon the serum glutamate in the affective disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is supported by findings of elevated serum and plasma glutamate levels in patients85,86 and reduction of plasma glutamate levels following treatment with selective serotonin reuptake inhibitors (SSRIs).87”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [85]
Citations
Cites
"Serotonin Depression"—A Biochemical Subgroup Within the Affective Disorders?
Åsberg, M., Thorén, P., Traskman, L., Bertilsson, L., & Ringberger, V. (1976) · Science · doi:10.1126/science.1246632 · Cited by 682
5-Hydroxytryptamine in the Hind-Brain of Depressive Suicides
Shaw, D. M., Camps, F. E., & Eccleston, E. G. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.505.1407 · Cited by 431
Graham, L. T., & Aprison, M. H. (1966) · Analytical Biochemistry · doi:10.1016/0003-2697(66)90110-2 · Cited by 387
KINETICS OF COMPETITIVE INHIBITION OF NEUTRAL AMINO ACID TRANSPORT ACROSS THE BLOOD‐BRAIN BARRIER
Pardridge, W. M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb07714.x · Cited by 367
VAN PRAAG, H. M., KORF, J., & PUITE, J. (1970) · Nature · doi:10.1038/2251259b0 · Cited by 249
Biogenic Amine Metabolites in Cerebrospinal Fluid of Depressed and Manic Patients
Mendels, J., Frazer, A., Fitzgerald, R. G., Ramsey, T. A., & Stokes, J. W. (1972) · Science · doi:10.1126/science.175.4028.1380 · Cited by 179
TOTAL AND FREE TRYPTOPHAN CONCENTRATION IN THE PLASMA OF DEPRESSIVE PATIENTS
Coppen, A., Eccleston, E. G., & Peet, M. (1973) · The Lancet · doi:10.1016/s0140-6736(73)93259-5 · Cited by 166
Biochemical post-mortem findings in depressed patients
Birkmayer, W., & Riederer, P. F. (1975) · Journal of Neural Transmission · doi:10.1007/bf01663627 · Cited by 118
Angst, J., Woggon, B., & Schoepf, J. (1977) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00346485 · Cited by 95
Møller, S., Kirk, L., & Honoré, P. (1980) · Journal of Affective Disorders · doi:10.1016/0165-0327(80)90021-x · Cited by 82
Research works printed but not linked: 2
- Munro HN (1979) Factors in the regulation of glutamate metabolism. In: Filer JLJ, Garattini S, Kare MR, Reynolds WA, Wurtman RJ (eds) Adv Biochem Physiol. Raven Press, New York, pp 55?68
- Stegink LD, Reynolds WA, Filer JLJ, Baker GL, Daabees TT, Pitkin RM (1979) Comparative metabolism of glutamate in the mouse, monkey, and man. In: Filer JLJ, Garattini S, Kare MR, Reynolds WA, Wurtman RJ (eds) Adv Biochem Physiol. Raven Press, New York, pp 85?102
Cited by
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders
Yüksel, C., & Öngür, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.016 · Cited by 493
Neuroinflammation and comorbidity of pain and depression
Walker, A. K., Kavelaars, A., Heijnen, C. J., & Dantzer, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008144 · Cited by 460
“Mitani and colleagues (2006) observed a positive correlation of plasma glutamate, glutamine, glycine, and taurine with Hamilton Depressive Rating Scale (HDRS) scores in depressed patients, as have others (Kim et al., 1982).”
BackgroundGut microbiome-wide association study of depressive symptoms
Radjabzadeh, D., Bosch, J. A., Uitterlinden, A. G., Zwinderman, A. H., Ikram, M. A., van Meurs, J. B. J., Luik, A. I., Nieuwdorp, M., Lok, A., van Duijn, C. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34502-3 · Cited by 434
Glutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Moriguchi, S., Takamiya, A., Noda, Y., Horita, N., Wada, M., Tsugawa, S., Plitman, E., Sano, Y., Tarumi, R., ElSalhy, M., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0252-9 · Cited by 357
Beyond Monoamines: Glutamatergic Function in Mood Disorders
Kugaya, A., & Sanacora, G. (2005) · CNS Spectrums · doi:10.1017/s1092852900010403 · Cited by 290
Ketamine and the next generation of antidepressants with a rapid onset of action
Machado-Vieira, R., Salvadore, G., DiazGranados, N., & Zarate, C. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.010 · Cited by 276
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Increased cerebrospinal fluid glutamine levels in depressed patients
Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R. J., & Pettegrew, J. W. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00284-x · Cited by 240
The role of the gut microbiota in dietary interventions for depression and anxiety
Bear, T. L. K., Dalziel, J. E., Coad, J., Roy, N. C., Butts, C. A., & Gopal, P. K. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa016 · Cited by 229
Maeng, S., & Zarate, C. A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0063-1 · Cited by 229
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Godfrey, K. E. M., Gardner, A. C., Kwon, S., Chea, W., & Muthukumaraswamy, S. D. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.015 · Cited by 206
Reznikov, L. R., Grillo, C. A., Piroli, G. G., Pasumarthi, R. K., Reagan, L. P., & Fadel, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05560.x · Cited by 201
Nasca, C., Bigio, B., Zelli, D., Nicoletti, F., & McEwen, B. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.96 · Cited by 194
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics
Lai, C.-Y., Scarr, E., Udawela, M., Everall, I., Chen, W. J., & Dean, B. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i1.102 · Cited by 153
Immunology of Major Depression
Müller, N. (2014) · Neuroimmunomodulation · doi:10.1159/000356540 · Cited by 174
The role of glutamate on the action of antidepressants
Hashimoto, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.013 · Cited by 170
GABA and glutamate systems as therapeutic targets in depression and mood disorders
Kendell, S. F., Krystal, J. H., & Sanacora, G. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.1.153 · Cited by 167
Maletic, V., Eramo, A., Gwin, K., Offord, S. J., & Duffy, R. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00042 · Cited by 166
Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders
SANACORA, G., ROTHMAN, D. L., MASON, G., & KRYSTAL, J. H. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.018 · Cited by 157
Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
Clinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160
Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression
Karolewicz, B., Szebeni, K., Gilmore, T., Maciąg, D., Stockmeier, C. A., & Ordway, G. A. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008985 · Cited by 158
Luborzewski, A., Schubert, F., Seifert, F. C., Danker‐Hopfe, H., Brakemeier, E., Schlattmann, P., Anghelescu, I. G., Colla, M., & Bajbouj, M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.02.003 · Cited by 154
The Role of Sigma Receptors in Depression
Bermack, J. E., & Debonnel, G. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj04005x · Cited by 142
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 144
Inflammatory Biomarkers and Depression
Müller, N., Myint, A.-M., & Schwarz, M. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9210-2 · Cited by 143
Müller, N., & Schwarz, M. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-2012-3 · Cited by 140
The role of NMDA receptors in the pathophysiology and treatment of mood disorders
Ghasemi, M., Phillips, C., Trillo, L., Miguel, Z. D., Das, D., & Salehi, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.017 · Cited by 138
Ma, X.-C., Dang, Y.-H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C.-G., & Hashimoto, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056053 · Cited by 114
The As and Ds of stress: Metabolic, morphological and behavioral consequences
Reagan, L. P., Grillo, C. A., & Piroli, G. G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.050 · Cited by 126
Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder
Chandley, M., Szebeni, K., Szebeni, A., Crawford, J. D., Stockmeier, C. A., Turecki, G., Miguel-Hidalgo, J. J., & Ordway, G. A. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120110 · Cited by 118
Roles of glutamate signaling in preclinical and/or mechanistic models of depression
Tokita, K., Yamaji, T., & Hashimoto, K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.016 · Cited by 110
Depression and antidepressants: molecular and cellular aspects
Lanni, C., Govoni, S. M., Lucchelli, A., & Boselli, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0055-x · Cited by 107
Amidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y.-K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 90
Schmidt, M. V., Trümbach, D., Weber, P., Wagner, K., Scharf, S. H., Liebl, C., Datson, N., Namendorf, C., Gerlach, T., Kühne, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4668-10.2010 · Cited by 91
“Research efforts on the biological foundations of MDD have therefore shifted toward the involvement of alternative neurotransmitter systems.”
BackgroundInfluentialAn update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Proteomic and Metabolomic Profiling of a Trait Anxiety Mouse Model Implicate Affected Pathways
Zhang, Y., Filiou, M. D., Reckow, S., Gormanns, P., Maccarrone, G., Kessler, M. S., Frank, E., Hambsch, B., Holsboer, F., Landgraf, R., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.008110 · Cited by 91
Low nNOS protein in the locus coeruleus in major depression
Karolewicz, B., Szebeni, K., Stockmeier, C. A., Konick, L., Overholser, J. C., Jurjus, G., Roth, B. L., & Ordway, G. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02792.x · Cited by 84
Millard, S. J., Weston–Green, K., & Newell, K. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.06.008 · Cited by 87
Busse, M., Busse, S., Myint, A.-M., Gos, T., Dobrowolny, H., Müller, U., Bogerts, B., Bernstein, H., & Steiner, J. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0562-0 · Cited by 86
Réus, G. Z., Abelaira, H. M., Stringari, R. B., Fries, G. R., Kapczinski, F., & Quevedo, J. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9281-2 · Cited by 81
Treadway, M. T., & Pizzagalli, D. A. (2014) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-4-5 · Cited by 76
Neuroimmune–endocrine crosstalk in schizophrenia and mood disorders
Müller, N., & Schwarz, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.1017 · Cited by 77
Gottschalk, M. G., Wesseling, H., Guest, P. C., & Bahn, S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu019 · Cited by 71
The role of excitatory amino acids in neuropsychiatric illness
(1990) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.2.1.44 · Cited by 71
Barbon, A., Caracciolo, L., Orlandi, C., Musazzi, L., Mallei, A., Via, L. L., Bonini, D., Mora, C., Tardito, D., Gennarelli, M., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.013 · Cited by 74
Dogra, S., & Conn, P. J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108687 · Cited by 71
Glutamate transporters: A key piece in the glutamate puzzle of major depressive disorder
Medina, A. M., Burke, S., Thompson, R. C., Bunney, W. E., Myers, R., Schatzberg, A. F., Akil, H., & Watson, S. J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.04.007 · Cited by 70
Soeiro‐de‐Souza, M. G., Salvadore, G., Moreno, R. A., Otaduy, M. C. G., Chaim, K. T., Gattaz, W. F., Zarate, C. A., & Machado‐Vieira, R. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.203 · Cited by 69
Catches, J. S., Xu, J., & Contractor, A. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.026 · Cited by 59
Poleszak, E., Właź, P., Szewczyk, B., Właź, A., Kasperek, R., Wróbel, A., & Nowak, G. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0630-9 · Cited by 63
Umehara, H., Numata, S., Watanabe, S., Hatakeyama, Y., Kinoshita, M., Tomioka, Y., Nakahara, K., Nikawa, T., & Ohmori, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-05121-6 · Cited by 63
Reduced GABAergic cortical inhibition in aging and depression
Lissemore, J. I., Bhandari, A., Mulsant, B. H., Lenze, E. J., Reynolds, C. F., Karp, J. F., Rajji, T. K., Noda, Y., Zomorrodi, R., Sibille, E. L., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0093-x · Cited by 63
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Hascup, K. N., Hascup, E. R., Humeidan, M., Glaser, P. E. A., Yoshitake, T., Mathé, A. A., Gerhardt, G. A., & Kehr, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.60 · Cited by 59
Shwartz, A., Betzer, O., Kronfeld, N., Kazimirsky, G., Cazacu, S., Finniss, S., Lee, H. K., Motiei, M., Dagan, S. Y., Popovtzer, R., et al. (2017) · Theranostics · doi:10.7150/thno.18914 · Cited by 59
Soeiro‐de‐Souza, M. G., Otaduy, M. C. G., Machado‐Vieira, R., Moreno, R. A., Nery, F. G., Leite, C. D. C., & Lafer, B. (2018) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.02.007 · Cited by 58
Zhang, X., Tang, Y., Maletić‐Savatić, M., Sheng, J., Zhang, X., Zhu, Y., Zhang, T., Wang, J., Tong, S., Wang, J., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.014 · Cited by 60
Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review
de Oliveira, M. R., Chenet, A. L., Duarte, A. R., Scaini, G., & Quevedo, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0680-6 · Cited by 57
Zhu, X., Nedelcovych, M. T., Thomas, A. G., Hasegawa, Y., Moreno-Megui, A., Coomer, W., Vohra, V., Saito, A., Perez, G., Wu, Y., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0177-7 · Cited by 57
Region-specific glutamate changes in patients with unipolar depression
Grimm, S., Luborzewski, A., Schubert, F., Merkl, A., Kronenberg, G., Colla, M., Heuser, I., & Bajbouj, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.04.018 · Cited by 52
“Increased glutamate levels were observed in serum (Kim et al., 1982), plasma (Altamura et al., 1993; Mauri et al., 1998; Mitani et al., 2006) and in post-mortem samples of frontal cortex (Hashimoto et al., 2007) of patients with major depressive disorder (MDD).”
BackgroundManna, S. S. S., & Umathe, S. N. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.04.023 · Cited by 51
Sild, M., Ruthazer, E. S., & Booij, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.014 · Cited by 50
The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
“Multiple studies have reported elevated glutamate content in the plasma of depressed patients compared to healthy subjects (Kim et al., 1982; Altamura et al., 1993, 1995; Mauri et al., 1998; Mitani et al., 2006; Kucukibrahimoglu et al., 2009).”
Immunologische Aspekte bei depressiven Störungen
Müller, N., & Schwarz, M. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2311-3 · Cited by 47
Glutamatergic system abnormalities in posttraumatic stress disorder
Nishi, D., Hashimoto, K., Noguchi, H., Hamazaki, K., Hamazaki, T., & Matsuoka, Y. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4052-5 · Cited by 44
Antidepressant activity and calcium signaling cascades
Paul, I. A. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.186 · Cited by 45
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 43
Hippocampal CA3 calcineurin activity participates in depressive‐like behavior in rats
Zhu, W., Shi, H., Wang, S., Wu, P., Ding, Z., & Lu, L. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07285.x · Cited by 34
Müller, N., & Bechter, K. (2013) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2013.04.004 · Cited by 37
Gruenbaum, B. F., Zlotnik, A. A., Frenkel, A., Fleidervish, I. A., & Boyko, M. (2022) · Metabolites · doi:10.3390/metabo12050459 · Cited by 37
Pain, Depression and Inflammation: Are Interconnected Causative Factors Involved?
Leonard, B. E. (2015) · Modern trends in psychiatry · doi:10.1159/000435930 · Cited by 36
Sharaha, U., Rodriguez‐Diaz, E., Sagi, O., Riesenberg, K., Salman, A., Bigio, I. J., & Huleihel, M. (2019) · Journal of Biophotonics · doi:10.1002/jbio.201800478 · Cited by 35
Sasaki, K., Othman, M. B., Ferdousi, F., Yoshida, M., Watanabe, M. M., Tominaga, K., & Isoda, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218923 · Cited by 35
Park, D. I., Dournes, C., Sillaber, I., Ising, M., Asara, J. M., Webhofer, C., Filiou, M. D., Müller, M. B., & Turck, C. W. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.39 · Cited by 34
Jiang, C., Zhou, T. G., Chen, W., Lin, D., Guo, A., Liu, Z., & Fei, E. (2020) · Biology · doi:10.3390/biology9110359 · Cited by 34
Metabotropic Glutamate Receptors: Potential Drug Targets for Psychiatric Disorders
Yasuhara, A., & Chaki, S. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004020020 · Cited by 34
Hillhouse, T. M., & Porter, J. H. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000014 · Cited by 34
Glutamate system as target for development of novel antidepressants
Catena-Dell’Osso, M., Fagiolini, A. M., Rotella, F., Baroni, S., & Marazziti, D. (2013) · CNS Spectrums · doi:10.1017/s1092852912000971 · Cited by 33
Ohnuma, T., & Arai, H. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.027 · Cited by 32
Sharaha, U., Rodriguez‐Diaz, E., Sagi, O., Riesenberg, K., Lapidot, I., Segal, Y., Bigio, I. J., Huleihel, M., & Salman, A. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05497 · Cited by 32
Halaris, A. E., & Cook, J. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_21 · Cited by 32
Peripheral Glutamate Levels in Schizophrenia: Evidence from a Meta-Analysis
Song, J., Viggiano, A., Monda, M., & De Luca, V. (2014) · Neuropsychobiology · doi:10.1159/000364828 · Cited by 29
Spíndola, L., Pan, P. M., Moretti, P. N. S., Ota, V., Santoro, M. L., Cogo‐Moreira, H., Gadelha, A., Salum, G. A., Manfro, G. G., Mari, J. D. J., et al. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.03.015 · Cited by 32
Sales, A. J., Maciel, I. D. S., Suavinha, A. C. D. R., & Joca, S. R. L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02145-4 · Cited by 31
Lei, Y., Yaroslavsky, I., & Tejani‐Butt, S. M. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.10.010 · Cited by 30
Recent advances in psychoneuroimmunology: Inflammation in psychiatric disorders
Debnath, M., Doyle, K., Langan, C., McDonald, C., Leonard, B., & Cannon, D. (2011) · Translational Neuroscience · doi:10.2478/s13380-011-0019-0 · Cited by 28
Owolabi, R. A., Akanmu, M. A., & Adeyemi, O. I. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.015 · Cited by 28
Wang, J., Zhang, K., Chen, X., Liu, X., Teng, H., Zhao, M., & Sun, Z. S. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00139 · Cited by 28
Takarada‐Iemata, M., Takarada, T., Hinoi, E., Taniura, H., & Yoneda, Y. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21145 · Cited by 28
Domin, H., Szewczyk, B., Pochwat, B., Woźniak, M., & Śmiałowska, M. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4495-3 · Cited by 27
Metadata
- Authors
- Kim, J. S., Schmid-Burgk, W., Claus, D., & Kornhuber, H. H.
- Affiliations
- Universität Ulm (DE)
- Venue
- Archiv f�r Psychiatrie und Nervenkrankheiten
- Published
- 1982-12
- Volume
- 232
- Issue
- 4
- Pages
- 299-304
- ISSN
- 0003-9373 (ISSN-L)
- 1433-8491
- OpenAlex
- W1971437356
- Cited by
- 189
- References
- 16
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 28 · 2020: 11 · 2019: 9 · 2018: 11 · 2017: 13 · 2016: 9 · 2015: 5 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 0.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- serum glutamate, depression, endogenous depression, neurotic depression, schizophrenia, schizoaffective disorder, antidepressants, medication effects, mood disorders, amino acid metabolism
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Depressive Disorder, Female, Glutamates, Humans, Male, Middle Aged, Psychotic Disorders, Schizophrenia, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.